Logomix

Logomix develops a genome engineering platform that enables large-scale genome construction and modification through its proprietary Geno-Writing technology, allowing the synthesis and rewriting of cellular genomes across multiple species. The company's Geno-Writing technology goes beyond conventional genome editing by enabling the de novo synthesis of entire genomes, providing capabilities for creating artificial cells with designed genetic configurations. Logomix's pipeline includes cellular systems spanning multiple species categories including bacteria, yeast, cultured animal cells, and human stem cells, enabling applications in biomanufacturing, pharmaceutical development, synthetic biology, and industrial biotechnology. The platform allows researchers and biotechnology companies to engineer cellular genomes with precision, creating optimized production strains for biologics, vaccines, enzymes, and other biologically derived products. By providing large-scale genome construction capabilities, Logomix addresses the growing demand for custom-designed organisms in fields ranging from drug discovery to sustainable manufacturing. Founded in 2019 and headquartered in San Carlos, United States, Logomix has raised approximately $22.6 million at the Series A stage from investors including Angel Bridge, Sand Hill Angels, JAFCO, UTokyo Innovation Platform, Globis Capital Partners, ITOCHU Technology Ventures, Delight Ventures, Mirai Creation Organization, Norinchukin Capital, JST, Mitsubishi UFJ Capital, Aozora, Sumitomo Mitsui Banking Corporation, and Resona Bank.